清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

医学 内科学 布仑妥昔单抗维多汀 肿瘤科 临床终点 化疗方案 无进展生存期 无容量 随机对照试验 化疗 癌症 淋巴瘤 霍奇金淋巴瘤 免疫疗法
作者
Sharon M. Castellino,Hongli Li,Alex F. Herrera,Angela Punnett,Michael LeBlanc,Susan K. Parsons,David C. Hodgson,Frank G. Keller,Richard A. Drachtman,Adam J. Lamble,Christopher J. Forlenza,Andrew Doan,Sarah C. Rutherford,Andrew M. Evens,Richard F. Little,Malcolm A. Smith,Joo Y. Song,Sonali M. Smith,Jonathan W. Friedberg,Kara M. Kelly
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 610-610 被引量:2
标识
DOI:10.1182/blood-2023-180107
摘要

Background: Approaches to therapy in pediatric and adult cHL have differed historically. Brentuximab vedotin (BV) is efficacious in pediatric patients (pts) with high-risk cHL when combined with chemotherapy and response based involved site radiation therapy (RT) ( Castellino. NEJM 2022). Inhibition of the PD-1 pathway, central to the pathogenesis of cHL, is safe and effective in children with relapsed HL but has not been evaluated in the frontline setting. Led by SWOG, the National Clinical Trials Network (NCTN) conducted the randomized, phase 3 trial S1826 to evaluate nivolumab (N)-AVD vs BV-AVD in pts ages ≥12 years (y) with newly diagnosed Stage 3-4 cHL. Methods: Eligible pts were randomized 1:1 to either 6 cycles of N-AVD or BV-AVD. At randomization enrollment was stratified by age, International Prognostic Score (IPS), and intent to use RT. Treating site of pts 12-17y, the subject of this subgroup analysis, declared intent to use RT for residual metabolically active lesions on the end of treatment PET per protocol. Recipients of BV-AVD were required to receive G-CSF prophylaxis vs optional with N-AVD. Dexrazoxane was permitted, but not mandated. Response and disease progression was assessed by investigators using the 2014 Lugano Classification. The primary endpoint was PFS; secondary endpoints included overall survival (OS), event-free survival (EFS), and safety. Results: Of 976 eligible pts enrolled (from 7/9/2019 to 10/5/2022): 24.3% (n=237) were 12-17 y and randomized to N-AVD (n=120) or BV-AVD (n=117). Median age was 15.6 y (range, 12-17.9 y), 50% of pts were male, 69% were white, 15% were black, and 18% were Hispanic. 27% had an IPS score 4-7. At the 2nd interim analysis (50% of total PFS events) the SWOG Data and Safety Monitoring Committee recommended reporting the primary results as the primary PFS endpoint crossed the protocol-specified conservative statistical boundary for the full trial. In the pediatric cohort, 6 PFS events were observed after N-AVD compared to 12 events after BV-AVD. At a median follow-up of 12.1 months, the PFS was compared between arms [HR 0.48, 95% CI 0.18-1.28, stratified one-sided logrank p=0.067) in the pediatric cohort; 1 y PFS: N-AVD, 94%, BV-AVD, 88% (Fig.1). There have been no deaths in this age group. Overall use of RT was 0.8% (2/237) and 79% of pediatric pts received dexrazoxane. The rate of grade (gr) ≥ 3 hematologic adverse events (AE) was 45% after N-AVD compared to 41% after BV-AVD, with 3% gr ≥ 3 febrile neutropenia and 1% with sepsis after either regimen, despite differences in GCSF use (59.2% N, 93.2% BV). Overall rates of immune related AEs (irAEs) (any gr) were low: pneumonitis (3.0% N vs 1% BV), and colitis (0% N vs 1% BV). Rash (any gr) was more common in BV-AVD (2% N vs 14% BV). Hypo/hyperthyroidism (any gr) was higher after N-AVD (2% N vs 0% BV). Rates of transaminitis were similar (ALT elevation: 42% N vs 54% BV). While sensory peripheral neuropathy was more frequent after BV-AVD (sensory: 18% N vs 29% BV; motor: 8% N vs 5% BV), only 1% was > grade 3. Discontinuation of N vs BV therapy occurred in 8.3% vs 2.6% of pediatric pts respectively, compared to 7.9% vs 21.1% of adults. Conclusions: In early follow-up, N-AVD and BV-AVD are well tolerated and associated with low rates of irAEs in pts ages 12-17 y. With 12.1 mos median follow-up the PFS benefit observed for N-AVD in pediatric pts mirrors that observed in the overall study. RT usage is lower, and cumulative doxorubicin dose is higher than historical pediatric cHL trials. The difference in rate of discontinuation between study arms and by age group needs further evaluation. Longer follow-up is needed to better define the roles of N-AVD and Bv-AVD for AS cHL. S1826 is a model NCTN trial, providing earlier access to novel agents and harmonization of treatment for adolescents and young adults with AS cHL. Funding: NIH/NCI/NCTN grants U10CA180888 and U10CA180819, U10CA180820, U10CA180821, U10CA180863, U10 CA180886; and Bristol-Myers Squibb. Bv provided by Seagen (Canada Only). Clinical Trial NCT03907488.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
沙海沉戈完成签到,获得积分0
10秒前
科研通AI2S应助科研通管家采纳,获得10
12秒前
jarrykim完成签到,获得积分10
30秒前
1分钟前
1分钟前
hongtao发布了新的文献求助10
1分钟前
nav完成签到 ,获得积分10
1分钟前
2分钟前
香蕉觅云应助科研通管家采纳,获得10
2分钟前
Owen应助科研通管家采纳,获得10
2分钟前
海藏进星辰完成签到,获得积分10
2分钟前
卷卷完成签到,获得积分10
2分钟前
2分钟前
ktw完成签到,获得积分10
2分钟前
kmzzy完成签到,获得积分10
3分钟前
科研通AI2S应助科研通管家采纳,获得10
4分钟前
5分钟前
5分钟前
一条摆摆的沙丁鱼完成签到 ,获得积分10
5分钟前
5分钟前
yyf发布了新的文献求助10
6分钟前
claud完成签到 ,获得积分0
6分钟前
yyf完成签到,获得积分10
6分钟前
ffdhdh完成签到,获得积分10
6分钟前
白天科室黑奴and晚上实验室牛马完成签到 ,获得积分10
7分钟前
8分钟前
Akim应助亦风采纳,获得10
8分钟前
8分钟前
亦风发布了新的文献求助10
8分钟前
情怀应助刘紫媛采纳,获得10
8分钟前
科研通AI2S应助亦风采纳,获得10
8分钟前
亦风完成签到,获得积分10
8分钟前
8分钟前
偷得浮生半日闲完成签到 ,获得积分10
9分钟前
jintian完成签到 ,获得积分10
9分钟前
9分钟前
fufufu123完成签到 ,获得积分10
9分钟前
桐桐应助科研通管家采纳,获得10
10分钟前
puzhongjiMiQ完成签到,获得积分10
10分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990469
求助须知:如何正确求助?哪些是违规求助? 3532166
关于积分的说明 11256513
捐赠科研通 3271046
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234